Analyst Sean Laaman from Morgan Stanley maintained a Buy rating on Disc Medicine and keeping the price target at $115.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sean Laaman has given his Buy rating due to a combination of factors surrounding Disc Medicine’s promising developments in their treatment pipeline. The initial Phase 2 data for DISC-0974 in treating anemia associated with myelofibrosis has shown positive results, including consistent decreases in hepcidin levels and increases in serum iron, which are crucial indicators of the drug’s efficacy. The treatment was generally well tolerated, with only mild adverse effects reported, suggesting a favorable safety profile.
Moreover, the management’s strategic plans to initiate a pivotal study in the first half of 2027, along with expansion into other anemia-related conditions, highlight the potential for broader applicability of their treatments. The company’s proactive approach in addressing logistical challenges and their commitment to advancing their pipeline further reinforce the positive outlook. These factors, combined with the company’s market position and upcoming catalysts, underpin Laaman’s optimistic Buy rating for Disc Medicine’s stock.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $110.00 price target.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year.